Adma Biologics Inc. (NASDAQ:ADMA) shares fell 0.6% during mid-day trading on Wednesday . The stock traded as low as $6.89 and last traded at $7.08, with a volume of 89,646 shares. The stock had previously closed at $7.12.
Several brokerages have recently issued reports on ADMA. Maxim Group reduced their price objective on Adma Biologics from $24.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, July 25th. Raymond James Financial Inc. cut Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st.
The stock has a 50-day moving average of $5.89 and a 200 day moving average of $6.56. The stock’s market capitalization is $91.23 million.
Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.11. Adma Biologics had a negative net margin of 231.85% and a negative return on equity of 1,293.57%. On average, equities analysts anticipate that Adma Biologics Inc. will post ($1.76) EPS for the current year.
A number of large investors have recently modified their holdings of the company. Iguana Healthcare Management LLC bought a new stake in shares of Adma Biologics during the second quarter valued at $744,000. Sabby Management LLC bought a new stake in shares of Adma Biologics during the second quarter valued at $595,000. Guggenheim Capital LLC increased its stake in shares of Adma Biologics by 36.3% in the second quarter. Guggenheim Capital LLC now owns 29,747 shares of the company’s stock valued at $177,000 after buying an additional 7,929 shares during the period. UBS Oconnor LLC increased its stake in shares of Adma Biologics by 111.3% in the second quarter. UBS Oconnor LLC now owns 71,174 shares of the company’s stock valued at $423,000 after buying an additional 37,497 shares during the period. Finally, Spark Investment Management LLC increased its stake in shares of Adma Biologics by 126.8% in the second quarter. Spark Investment Management LLC now owns 31,300 shares of the company’s stock valued at $186,000 after buying an additional 17,500 shares during the period. Institutional investors own 73.91% of the company’s stock.
Adma Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for Adma Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adma Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.